Pharmaceutically active sulfonyl hydrazide derivatives

Details Pharmaceutically active sulfonyl hydrazide derivatives Pharmaceutically active sulfonyl hydrazide derivatives

2000-09-28

2008-10-07

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S614000, C546S268100, C564S081000

Reexamination Certificate

active

07432286

ABSTRACT:
The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation. In Formula (I) Ar1and Ar2are independently from each other an unsubstituted or substituted aryl or beteroaryl group, X1and X2are independently from each other O or S; R1, R2, R3are independently from each other hydrogen or a C1-C6-alkyl substituent or R1forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; or R2and R3form a substituted or unsubstituted 5-6-membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubstituted or substituted 4-8 membered heterocycle containing at least one heteroatom, or G is a substituted or unstibstituted C1-C6-alkyl group.

REFERENCES:
patent: 0 330 065 (1989-08-01), None
patent: 98 49188 (1998-11-01), None
patent: WO 01/23378 (2001-04-01), None
R. Raja Reddy et al.: “New hypoglycemic agents-Part XVI: synthesis and evaluation of N3-aryl-N1-′4-′(3, 4-dihydro-3-oxo-2H-1, 4-benzoxazin-2-yl) acetic acid hydrazidosulfonyllphenyll ureas/thioureas” Indian Journal of Heterocyclic Chemistry, vol. 7, No. 3, pp. 185-188.
Xie Xiaoling et al.: “Crystal structure of JNK3: a kinase implicated in neuronal apoptosis” Structure, 6 (8), pp. 983-991, 1998.
Derek D. Yang et al.: “Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene” Nature, 389 (6653), pp. 865-870, 1997.
Derek D. Yang et al.: “Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2” Immunity, 9, pp. 575-585, 1998.
Kanaga Sabapathy et al.: “JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development” Current Biology, 3, pp. 116-125, 1999.
Yoshihiro Kumage et al.: “Human c-Jun N-terminal kinase expression and activation in the nervous system” Brain Res. Mol. Brain Res., 67 (1), pp. 10-17, 1999.

Affiliated with

Also associated with

Rating

Pharmaceutically active sulfonyl hydrazide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active sulfonyl hydrazide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active sulfonyl hydrazide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4017027